ARROWHEAD PUBLISHERS/CONFERENCES - PRWeb Press Release Account Feed http://www.rsspad.com/rss2a/123637.xml ARROWHEAD PUBLISHERS/CONFERENCES - Press Releases en xml@emediawire.com xml@emediawire.com 30 Arrowhead-Spectra's Expert Opinion Event on Pharmaceutical Pricing and Reimbursement to Take Place on 29th May 2008 in London, UK http://www.prweb.com/releases/2008/04/prweb866024.htm This one-day event will be an essential platform to explore pricing policies, the needs of social systems, and the impact of low-cost Indian generics on European markets. (PRWeb Apr 23, 2008)

Read the full story at http://www.prweb.com/releases/2008/04/prweb866024.htm

]]> http://www.prweb.com/releases/2008/04/prweb866024.htm Arrowhead Announces the Agenda for its 2nd Annual Drug Delivery Summit in San Francisco, California on May 1st and 2nd, 2008 http://www.prweb.com/releases/2008/03/prweb764834.htm Arrowhead Conferences has announced the agenda for its 2nd Annual Drug Delivery Summit: New Technologies and Commercialization Trends in San Francisco, California on May 1st and 2nd, 2008. (PRWeb Mar 13, 2008)

Read the full story at http://www.prweb.com/releases/2008/03/prweb764834.htm

]]> http://www.prweb.com/releases/2008/03/prweb764834.htm Arrowhead Conferences' 2nd Annual Drug Delivery Summit to Take Place May 1st-2nd, 2008 in San Francisco http://www.prweb.com/releases/drug/delivery/prweb723203.htm Arrowhead Publishers and Conferences is proud to announce that it is hosting its 2nd Annual Drug Delivery Summit: New Technologies and Commercialization Trends in San Francisco, California on May 1st and 2nd, 2008. (PRWeb Feb 26, 2008)

Read the full story at http://www.prweb.com/releases/drug/delivery/prweb723203.htm

]]> http://www.prweb.com/releases/drug/delivery/prweb723203.htm New Insights into the Global Market for Pain Management http://www.prweb.com/releases/2007/11/prweb568982.htm According to Arrowhead Publishers' new report entitled The Global Pain Therapeutics Market: Market Analysis, R&D Pipelines and Competitive Landscape, one in five people suffer from moderate to severe chronic pain, and one in three is unable or less able to maintain an independent lifestyle due to their pain. The value of the pharmaceutical market for pain relief in 2007 reflects this seeming worldwide epidemic of pain. By the end of 2007, the value of this market will top $32 billion. (PRWeb Nov 14, 2007)

Read the full story at http://www.prweb.com/releases/2007/11/prweb568982.htm

]]> http://www.prweb.com/releases/2007/11/prweb568982.htm New Pain Therapeutics Summit 2007 Announced http://www.prweb.com/releases/2007/07/prweb537905.htm Arrowhead Conferences' http://www.arrowheadpublishers.com/conferences/paintherapeutics2007/index.php [Pain Therapeutics Summit 2007] brings together leaders from the pharmaceutical community to discuss new avenues of research in the field of pain therapeutics and the latest advances in the field.At this conference, hear from experts in the field regarding new targets for pain relief in the areas of neuropathic pain, nociceptive pain, migraine pain, cancer pain, chronic pain and inflammatory conditions. Moreover, special consideration will be given to the roles that drug delivery and devices will play in the future management of pain. (PRWeb Jul 10, 2007)

Read the full story at http://www.prweb.com/releases/2007/07/prweb537905.htm

]]> http://www.prweb.com/releases/2007/07/prweb537905.htm HIV and Hepatitis Therapies Continue to Drive Revenues in Antiviral Market http://www.prweb.com/releases/2007/05/prweb528008.htm According to Arrowhead Publishers' new report entitled The Global Anti-Virals Market: R&D Pipelines, Market Analysis and Competitive Landscape, the anti-infectives market is currently valued at US$66.5 billion with antiviral agents accounting for 24% of sales (excluding vaccines which target viral infectious diseases). (PRWeb May 23, 2007)

Read the full story at http://www.prweb.com/releases/2007/05/prweb528008.htm

]]> http://www.prweb.com/releases/2007/05/prweb528008.htm Arrowhead Publishers' New Study Reveals Trends in Pharmaceutical Clinical Trial Outsourcing to Emerging Markets http://www.prweb.com/releases/2007/05/prweb525094.htm Offshoring clinical trials to emerging markets around the world is receiving increasing attention as a very attractive alternative. This follows as a natural reaction to already successful offshoring activities in the IT industry. (PRWeb May 10, 2007)

Read the full story at http://www.prweb.com/releases/2007/05/prweb525094.htm

]]> http://www.prweb.com/releases/2007/05/prweb525094.htm Arrowhead Publishers -- A Leading Provider of Market Research and Business Intelligence for the Pharmaceutical and Biotech Industries -- Announces New Website and Online Store http://www.prweb.com/releases/2007/04/prweb515464.htm Arrowhead Publishers, a leading provider of market research and business intelligence studies recently announced the availability of its recently re-designed website at www.arrowheadpublishers.com. (PRWeb Apr 3, 2007)

Read the full story at http://www.prweb.com/releases/2007/04/prweb515464.htm

]]> http://www.prweb.com/releases/2007/04/prweb515464.htm Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and Information Technology Set to Revolutionize New Drug Development http://www.prweb.com/releases/2007/03/prweb512279.htm According to Arrowhead Publishers' new report entitled Innovations and Trends in Clinical Trials, the clinical trials industry has clear potential for strong growth in the future, driven by technological and scientific advances. This trend is complemented by the development of new trial designs, with a view to rationalizing and accelerating the drug discovery process by identifying failures at an earlier stage. Such modifications are increasingly receiving regulatory approvals and encouragement, as agencies become more aware of the benefits of such strategies. (PRWeb Mar 20, 2007)

Read the full story at http://www.prweb.com/releases/2007/03/prweb512279.htm

]]> http://www.prweb.com/releases/2007/03/prweb512279.htm Arrowhead Conferences' Drug Delivery 2007 to Take Place April 9th-11th 2007 in San Francisco http://www.prweb.com/releases/2007/02/prweb505543.htm Drug Delivery 2007 has been organized to provide a critical examination of the drug delivery industry as well as insight from key industry leaders concerning cutting edge drug delivery technology, structuring mutually beneficial deals and the drug delivery industry's impact on the field of biotechnology. (PRWeb Feb 19, 2007)

Read the full story at http://www.prweb.com/releases/2007/02/prweb505543.htm

]]> http://www.prweb.com/releases/2007/02/prweb505543.htm Unmet Need Drives Innovation in Neurodegenerative Disorder Therapy Market http://www.prweb.com/releases/2007/02/prweb504885.htm With a market size of US$14.5 billion in 2005 and an anticipated value of US$16.5 billion in 2006, the neurodegenerative market represents a valuable, fast-growing opportunity in the pharma/biotech industry. An estimated 22 million people worldwide are affected by neurodegenerative disorders. (PRWeb Feb 15, 2007)

Read the full story at http://www.prweb.com/releases/2007/02/prweb504885.htm

]]> http://www.prweb.com/releases/2007/02/prweb504885.htm Innovation, New Indications and Strong Clinical Efficacy Drive Monoclonal Antibody Market into 2007 http://www.prweb.com/releases/2007/01/prweb496656.htm In 2005, the antibodies market was valued at an estimated US$14 billion, accounting for over 24 percent of the total protein therapeutics market. According to Arrowhead Publishers' new report Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight the value of this market is set to reach more than $16 billion in 2006. (PRWeb Jan 12, 2007)

Read the full story at http://www.prweb.com/releases/2007/01/prweb496656.htm

]]> http://www.prweb.com/releases/2007/01/prweb496656.htm Challenges and Opportunities in the Global Protein Therapeutics Market http://www.prweb.com/releases/2006/12/prweb491667.htm The global protein therapeutics market was valued at US $57 billion in 2005, according to Arrowhead Publishers' new report The Global Protein Therapeutics Market - Market Dynamics and Pipeline Analysis. Biotechnology has made notable inroads in the field of protein therapeutics, resulting in some of the key products presently available in the category. (PRWeb Dec 18, 2006)

Read the full story at http://www.prweb.com/releases/2006/12/prweb491667.htm

]]> http://www.prweb.com/releases/2006/12/prweb491667.htm Growth in Biologics Market Continues to Drive Injectable Drug Delivery Industry http://www.prweb.com/releases/2006/10/prweb449657.htm As competition in the pharmaceutical marketplace grows, companies are increasingly looking towards the drug delivery industry to maximize revenues and combat generic competitors. The search for more efficient drug delivery systems is also being driven by the rise in patient demand, healthcare and pharma cost containment, as much as by medical and technological advances. (PRWeb Oct 17, 2006)

Read the full story at http://www.prweb.com/releases/2006/10/prweb449657.htm

]]> http://www.prweb.com/releases/2006/10/prweb449657.htm Biologics Continue to Drive Strong Growth in Rheumatoid Arthritis Market http://www.prweb.com/releases/2006/09/prweb439842.htm The market for rheumatoid arthritis therapeutics has experienced remarkably strong growth during the past five years due to the introduction of the biological response modifiers (BRMs) to treatment regimens. Total sales of these products are expected to reach approximately $10 billion in 2006, according to a new report from Arrowhead Publishers entitled Rheumatoid Arthritis: Market Trends and R&D Insights. (PRWeb Sep 21, 2006)

Read the full story at http://www.prweb.com/releases/2006/09/prweb439842.htm

]]> http://www.prweb.com/releases/2006/09/prweb439842.htm The Prescribing Data Restriction Program (PDRP): Implications and Strategies for Moving Forward http://www.prweb.com/releases/2006/09/prweb436217.htm Since the mid-1990s, pharma companies have devised their sales and marketing strategies based on Rx data. However, with the introduction of the AMA's Prescribing Data Restriction Program (PDRP) opt-out program in July 2006, pharma companies need to evaluate the impact of PDRP violation, mediate their PDRP compliance strategies, and revisit their existing Sales Force Effectiveness (SFE) practices. (PRWeb Sep 13, 2006)

Read the full story at http://www.prweb.com/releases/2006/09/prweb436217.htm

]]> http://www.prweb.com/releases/2006/09/prweb436217.htm Diabetes - A Growing Opportunity for Investment http://www.prweb.com/releases/2006/08/prweb420697.htm Diabetes is one of the largest therapeutic segments of global pharmaceutical sales and during the last 10 years it has grown by a compound average growth rate of nearly 20% from around US$4 billion in 1995 to over US$17 billion in 2005. (PRWeb Aug 7, 2006)

Read the full story at http://www.prweb.com/releases/2006/08/prweb420697.htm

]]> http://www.prweb.com/releases/2006/08/prweb420697.htm Biotechnology Continues to Break Ground in Autoimmune and Inflammatory Disease Treatment http://www.prweb.com/releases/2006/05/prweb380635.htm According to Arrowhead Publishers’ new report entitled Biotech in Autoimmune and Inflammatory Disease 2006, 2nd Ed., the value of biological drugs indicated for autoimmune diseases, which affect up to 5% of the total world population, was roughly $11 billion in 2005. Remicade, Enbrel, Humira and Avonex currently lead the autoimmune field. These drugs are transforming the treatment of autoimmune diseases. In addition, novel therapies for psoriasis, asthma, and lupus will in the near future add tremendous revenue to an already rapidly growing field. (PRWeb May 4, 2006)

Read the full story at http://www.prweb.com/releases/2006/05/prweb380635.htm

]]> http://www.prweb.com/releases/2006/05/prweb380635.htm New Report from Arrowhead Publishers Provides Insight into Pharmaceutical Pricing, Reimbursement and Parallel Trade http://www.prweb.com/releases/2006/03/prweb359410.htm The need of pharmaceutical companies to make profit in order to sustain its operations in the long term is pitched against the cost-payer’s need to save money. The balance between the two must be sought in order to optimise pharmaceutical pricing strategies, although the task is made more difficult by the fact that this equilibrium is often a shifting ground. (PRWeb Mar 21, 2006)

Read the full story at http://www.prweb.com/releases/2006/03/prweb359410.htm

]]> http://www.prweb.com/releases/2006/03/prweb359410.htm New Report Reveals Cancer Market Trends and Emerging Therapies http://www.prweb.com/releases/2005/12/prweb316616.htm Together, the four major cancer markets, which include colorectal, prostate, lung and breast cancer were valued at well over $16 billion in 2005, which was an increase of 14 percent in value since 2004. Driving this growth are innovative new products, line extensions for existing products, and the coming of age of the biotech industry. (PRWeb Dec 1, 2005)

Read the full story at http://www.prweb.com/releases/2005/12/prweb316616.htm

]]> http://www.prweb.com/releases/2005/12/prweb316616.htm New Report Examines Biotech Giant Amgen’s Success and Future Direction http://www.prweb.com/releases/2005/07/prweb264769.htm Amgen is the world’s largest biotechnology company and the eighth largest pharmaceutical company worldwide, with revenues reaching $10 billion in 2004. Arrowhead Publishers’ new report takes a detailed look at the company’s many successes and its strategy for the future.(http://www.arrowheadpublishers.com/Amgen.html) (PRWeb Jul 26, 2005)

Read the full story at http://www.prweb.com/releases/2005/07/prweb264769.htm

]]> http://www.prweb.com/releases/2005/07/prweb264769.htm A New Look at the US and European Prescription Generic Markets http://www.prweb.com/releases/2005/07/prweb260730.htm The US generics market was estimated at US$18.1 billion in 2004; the leading European generics markets together totalled between US$10–US$11 billion for the same period. US and European Prescription Generic Markets: An Examination of Commercial and Regulatory Contrasts takes a look at the reasons for this disparity in value. (PRWeb Jul 13, 2005)

Read the full story at http://www.prweb.com/releases/2005/07/prweb260730.htm

]]> http://www.prweb.com/releases/2005/07/prweb260730.htm New Insights into the Global Pain Market-Post Vioxx http://www.prweb.com/releases/2005/05/prweb238463.htm The dynamics of the pain market have been altered greatly over the past year. The troubles surrounding the multi-billion dollar Cox-II class has created a void in the marketplace. Pain Therapeutics 2005 not only analyzes this market but also the global markets for opioids, anticonvulsants, triptans, and traditional NSAIDs (http://www.arrowheadpublishers.com/PainTherapeutics.html) (PRWeb May 11, 2005)

Read the full story at http://www.prweb.com/releases/2005/05/prweb238463.htm

]]> http://www.prweb.com/releases/2005/05/prweb238463.htm Alliances and Outsourcing Having Major Impact on Pharma Industry http://www.prweb.com/releases/2005/03/prweb219520.htm Evidence of the growing emphasis on alliances and external collaborations as a route to success in the pharma industry is highlighted by the fact that partnerships within the biopharmaceutical sector are currently being formed at the rate of $5 billion per year, according to Arrowhead Publishers' new report Strategies for Innovation in Pharmaceutical R&D: Enhancing R& Through Biotech Alliances and CRO Outsourcing(http://www.arrowheadpublishers.com/StrategiesforInnovationinPharmaceuticalRandD.html) (PRWeb Mar 22, 2005)

Read the full story at http://www.prweb.com/releases/2005/03/prweb219520.htm

]]> http://www.prweb.com/releases/2005/03/prweb219520.htm Biogenerics Moving Closer to Commercialization http://www.prweb.com/releases/2005/01/prweb194120.htm Biogenerics will have a major impact on the worldwide pharmaceutical marketplace according to Arrowhead Publishers' new report Biogenerics: Challenges and Promise(http://www.arrowheadpublishers.com/Biogenerics.html). (PRWeb Jan 12, 2005)

Read the full story at http://www.prweb.com/releases/2005/01/prweb194120.htm

]]> http://www.prweb.com/releases/2005/01/prweb194120.htm Cancer Vaccines Set to Make Major Impact on Cancer Market http://www.prweb.com/releases/2005/01/prweb193798.htm The value of the market for cancer vaccines has the potential to reach $6 billion by 2010, according to Arrowhead Publishers, who have just released their new report Cancer Vaccines: Measuring Market Potential. (http://www.arrowheadpublishers.com/CancerVaccines.html) (PRWeb Jan 5, 2005)

Read the full story at http://www.prweb.com/releases/2005/01/prweb193798.htm

]]> http://www.prweb.com/releases/2005/01/prweb193798.htm